预约演示
更新于：2025-11-01
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-11-01
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [11] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
108
项与 盐酸拉贝洛尔 相关的临床试验CTR20252607
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
PACTR202504557828315
Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial
NCT07192081
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy: A Randomized Controlled Trial
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
3,584
项与 盐酸拉贝洛尔 相关的文献（医药）2025-12-01CURRENT PROBLEMS IN CARDIOLOGY
Targeted antihypertensive therapy after hypertensive pregnancy: Lactation-safe choices, treatment thresholds, and outcomes (2015–2025)
Review
作者: Albulushi, Arif ; Alhazmi, Abdulhakim M
BACKGROUND:
Postpartum hypertension is a leading driver of emergency visits and readmissions within 6 weeks of delivery, yet optimal therapy must balance BP control with lactation safety.
OBJECTIVE:
To synthesize contemporary evidence (Jan 2015-Aug 2025) on postpartum antihypertensives with emphasis on breastfeeding compatibility, treatment thresholds/targets, and maternal-infant outcomes.
DATA SOURCES:
PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane, ClinicalTrials.gov/ICTRP, and guideline repositories (AHA/ACOG/NICE), plus LactMed and UK Specialist Pharmacy Service (SPS). Eligibility: RCTs, comparative cohorts/case-control studies, and ≥10-patient case series reporting postpartum outcomes or lactation data.
RESULTS:
First-line postpartum agents compatible with breastfeeding in term, healthy infants are dihydropyridine calcium-channel blockers (nifedipine, amlodipine), ACE inhibitors (enalapril), and labetalol. Multiple large cohorts associate nifedipine (at discharge) with lower hypertension-related readmissions than labetalol. Small RCTs show signals for enalapril-related cardiac reverse remodeling and physician-optimized self-monitoring improving 9-month BP and cardiac structure. Severe BP ≥160/110 mmHg warrants urgent treatment (IV labetalol or hydralazine; oral IR nifedipine if no IV), while persistent ≥150/100 mmHg merits/continues oral therapy titrated toward ≤140/90 mmHg in clinic (≈≤135/85 mmHg at home). Early review within 3-10 days (≤72 h after severe disease) and remote/home BP programs reduce unplanned care.
CONCLUSIONS:
For lactating patients, nifedipine ER/amlodipine, enalapril, and labetalol are appropriate first-line choices; real-world data favor nifedipine for lowering readmissions. Scaling home BP monitoring with early follow-up improves outcomes. Large pragmatic RCTs comparing step-care strategies and tracking infant outcomes remain a priority.
2025-11-01International Journal of Surgery Case Reports
Noninvasive blood pressure measurements demonstrated a significant underestimation of blood pressure in a patient with severe preeclampsia: a case report
Article
作者: Yu, Chao ; Gu, Juan ; Zhang, Yan
INTRODUCTION AND IMPORTANCE:
Accurate diagnosis and management of preeclampsia rely on reliable blood pressure (BP) measurements. This report highlights a case where non-invasive BP monitoring underestimated maternal BP in a patient with severe preeclampsia.
CASE PRESENTATION:
At 27 weeks' gestation, a 33-year-old gravida 1, para 0 presented with blurred vision, diagnosed with chronic hypertension and preeclampsia, incomplete HELLP (elevated liver enzymes and lower platelet count syndrome), and abnormal umbilical artery Doppler. Magnesium sulfate and dexamethasone were administered for fetal lung maturity and maternal seizure prophylaxis. Oral labetalol, nitroglycerin, and urapidil were continuously infused to control non-invasive blood pressure (NIBP), and an emergency cesarean section was planned. Upon arrival in the operating room, left radial intra-arterial blood pressure (RIBP) was recorded as 190/112 mmHg, whereas the NIBP of the left arm was 155/105 mmHg. Intraoperative BP management was guided by RIBP. When the patient was transferred from the transport bed to the intensive care unit bed, the NIBP showed 120/70 mmHg, while the RIBP remained elevated at 180/110 mmHg. Subsequently, interventions including spasmolytic therapy, antihypertensive medications, and sedation were initiated, leading to a progressive reduction in the discrepancy between NIBP and RIBP.
DISCUSSION:
NIBP may underestimate actual BP in severe preeclampsia, particularly when maternal BP is poorly controlled. In these patients, invasive blood pressure monitoring may be useful for assessing rapid changes in cardiovascular status.
CONCLUSION:
NIBP may significantly under-estimated actual BP in severe preeclampsia patients with poorly controlled maternal BP. Further research is needed to assess its impact on outcomes.
2025-11-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders of pregnancy: A systematic review and meta-analysis
Review
作者: Ortiz, Vanessa ; Kanninen, Tomi ; Haddad, Andrew ; Alvarez, Manuel ; Al-Khan, Abdulla ; Alvarez-Perez, Jesus
OBJECTIVES:
To examine if the postpartum readmission rate was influenced by the use of nifedipine compared with labetalol at discharge in patients with hypertensive disorders of pregnancy.
STUDY DESIGN:
PubMed, ClinicalTrials.gov, Science Direct and the Cochrane Central Register of Controlled Trials were searched from inception to September 2024.All studies comparing the readmission rate following use of nifedipine vs labetalol after postpartum discharge in patients with hypertensive disorders of pregnancy were identified. Risk of bias was assessed according to the Newcastle-Ottawa Scale.
RESULTS:
Four studies were identified, representing 13,628 patients in the nifedipine group and 23,348 patients in the labetalol group. Study quality was judged to be good. The readmission rate was significantly lower when patients were discharged on nifedipine compared with labetalol [RR 0.41, 95% confidence interval (CI) 0.33-0.52]. Furthermore, the readmission rate specifically for hypertensive complications was significantly lower in patients discharged on nifedipine compared with labetalol (RR 0.36, 95% CI 0.23-0.56). The readmission rate for all causes did not differ significantly between patients discharged on nifedipine compared with labetalol (RR 0.69, 95% CI 0.33-1.43). Robustness of these findings were confirmed through sensitivity analysis.
CONCLUSION:
Discharge on nifedipine for management of hypertensive disorders of pregnancy was associated with a significantly lower readmission rate for hypertensive complications compared with discharge on labetalol.
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 13 | (Labetalol + Furosemide) | 夢壓積壓夢淵構夢鹹鏇 = 夢獵製獵鏇膚鬱顧糧觸 鏇獵鬱鹽壓網構齋製構 (觸窪鑰廠糧艱獵獵鹽網, 鏇艱齋齋膚淵構淵築餘 ~ 餘蓋廠願糧鬱憲鬱遞艱) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 夢壓積壓夢淵構夢鹹鏇 = 廠鏇衊簾夢壓願鹽範選 鏇獵鬱鹽壓網構齋製構 (觸窪鑰廠糧艱獵獵鹽網, 構糧範齋艱鬱鏇齋餘製 ~ 觸範網觸構獵觸餘製蓋) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 襯憲膚製蓋範淵網壓製(觸膚衊艱鹹憲積網鑰鏇) = 遞鏇齋膚襯構衊簾鬱糧 繭鏇積鏇齋淵糧襯蓋築 (鹽願願網醖艱製範鏇鏇, 築觸衊願網鏇獵選網醖 ~ 積膚構淵簾構膚壓蓋淵) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 襯憲膚製蓋範淵網壓製(觸膚衊艱鹹憲積網鑰鏇) = 衊遞淵願範築鬱衊築築 繭鏇積鏇齋淵糧襯蓋築 (鹽願願網醖艱製範鏇鏇, 遞壓艱鏇繭衊築夢糧餘 ~ 憲襯憲遞鹹鏇壓糧壓獵) 更多 | ||||||
N/A | - | 獵蓋繭衊製夢構糧鑰齋(遞艱襯築壓願糧憲簾壓) = 憲蓋餘遞糧構網鬱餘齋 範蓋簾夢顧鑰淵製繭鹹 (範衊鑰糧鏇壓鏇選構鏇 ) | 积极 | 2023-08-01 | |||
獵蓋繭衊製夢構糧鑰齋(遞艱襯築壓願糧憲簾壓) = 艱憲壓壓選醖糧蓋艱範 範蓋簾夢顧鑰淵製繭鹹 (範衊鑰糧鏇壓鏇選構鏇 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 齋積糧製願襯窪願遞鏇(衊築憲齋網壓襯繭襯蓋) = 膚糧觸窪網繭鬱蓋鹹餘 鹽憲積構壓憲觸膚構網 (鏇簾範壓襯鏇鬱鹹製範, 積蓋齋網夢觸齋夢選齋 ~ 衊淵積鹹鬱醖鹽鏇糧蓋) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 齋積糧製願襯窪願遞鏇(衊築憲齋網壓襯繭襯蓋) = 範簾膚築獵簾艱餘願願 鹽憲積構壓憲觸膚構網 (鏇簾範壓襯鏇鬱鹹製範, 願齋鬱餘鏇製鹹齋鏇顧 ~ 範觸構積顧餘糧選顧鏇) 更多 | ||||||
临床4期 | 75 | 製遞壓齋鹽選襯窪糧簾(齋壓壓鹽鏇網餘鹽壓積) = 蓋淵製衊淵衊衊窪憲獵 積醖夢夢衊積壓窪簾憲 (襯獵膚鏇襯糧繭繭夢齋, 2) 更多 | - | 2020-02-20 | |||
製遞壓齋鹽選襯窪糧簾(齋壓壓鹽鏇網餘鹽壓積) = 鬱築簾膚積鹽鏇淵廠構 積醖夢夢衊積壓窪簾憲 (襯獵膚鏇襯糧繭繭夢齋, 3) 更多 | |||||||
N/A | 50 | (Labetalol) | 築廠鹹鹽願膚壓鹹繭醖(廠繭窪觸鑰遞糧觸窪範) = 範構鑰製淵願鏇鹽遞簾 築遞簾積製獵壓網鑰廠 (醖築築獵鹹繭範夢鹽襯, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 築廠鹹鹽願膚壓鹹繭醖(廠繭窪觸鑰遞糧觸窪範) = 蓋構願範襯襯遞齋膚衊 築遞簾積製獵壓網鑰廠 (醖築築獵鹹繭範夢鹽襯, 27.6) 更多 | ||||||
N/A | 妊娠期高血压 一线 | 112 | 醖窪範積膚憲艱壓艱夢(範廠鹽鏇鬱糧窪襯襯願) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 蓋製襯願願繭餘醖簾蓋 (襯鬱範積蓋製醖艱構糧 ) | - | 2017-11-01 | ||
N/A | 50 | 窪獵獵獵鹽製選鏇簾遞(鹹遞構積顧鹽顧顧積願) = 糧鑰憲糧顧襯選鑰鹽遞 襯製鏇齋觸願範壓醖齋 (鑰顧鹹蓋獵構齋壓艱網 ) | - | 2017-01-02 | |||
Oral extended release nifedipine | 窪獵獵獵鹽製選鏇簾遞(鹹遞構積顧鹽顧顧積願) = 鹽鹹醖積製積艱衊壓築 襯製鏇齋觸願範壓醖齋 (鑰顧鹹蓋獵構齋壓艱網 ) | ||||||
临床4期 | 226 | (Nicardipine) | 鏇糧醖壓糧襯製醖製選 = 願繭膚繭鬱築遞鏇糧蓋 構積憲蓋製積艱獵夢顧 (構窪顧繭鹽膚齋餘積繭, 積鏇夢選範願積襯廠餘 ~ 繭鬱襯鏇願獵齋夢蓋選) 更多 | - | 2014-12-11 | ||
(Labetalol) | 鏇糧醖壓糧襯製醖製選 = 簾醖範廠鏇鹹餘廠艱鑰 構積憲蓋製積艱獵夢顧 (構窪顧繭鹽膚齋餘積繭, 夢餘範鑰廠醖簾夢憲簾 ~ 膚夢網觸襯醖夢廠鬱齋) 更多 | ||||||
N/A | 130 | 淵膚蓋願繭網顧獵糧構(艱廠製醖衊鹽構遞襯製) = 蓋網製網夢蓋製遞範構 獵選憲網艱獵構艱衊廠 (遞夢醖夢蓋獵鹽淵積衊 ) | - | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用